Ivabradine Sandoz (Ivabradine Oxalate)

Ivabradine works by selectively blocking the funny (If) current in the sino‑atrial node. This current is responsible for the spontaneous depolarisation that sets the heart’s rhythm. Inhibition slows the pacemaker activity, leading to a lower resting heart rate without affecting myocardial contractility or blood pressure.

The dose of Ivabradine Sandoz is individualized by the prescribing clinician based on the patient’s heart‑rate, clinical condition, and tolerance. The prescriber determines the appropriate starting dose and any subsequent adjustments; no standard dosing regimen is provided here.

Safety data for Ivabradine in pregnancy and lactation are limited, and the product is generally not recommended for use in these situations. Clinicians should weigh potential benefits against unknown risks, and alternative therapies with established safety profiles are preferred for pregnant or nursing individuals.

To order Ivabradine Sandoz, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Both Ivabradine and beta‑blockers lower heart rate, but they act via different mechanisms. Beta‑blockers block adrenergic receptors and affect contractility and blood pressure, whereas Ivabradine selectively inhibits the If current without influencing contractility or systemic pressure. Ivabradine is often considered when beta‑blockers are contraindicated or not tolerated.

Ivabradine Sandoz tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Ivabradine Sandoz is taken orally as a tablet, usually with or without food as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not chewed or crushed, to ensure consistent absorption and therapeutic effect.

The most serious risks include severe bradycardia, atrial fibrillation, and marked hypotension, which can lead to dizziness, fainting or syncope. Patients should be monitored for new‑onset arrhythmias, unusually low heart rates, or significant drops in blood pressure, and seek medical attention promptly if these occur.

Ivabradine should not be used in patients with acute decompensated heart failure, severe hepatic impairment, sick sinus syndrome, or those in permanent atrial fibrillation. It is also contraindicated in individuals taking strong CYP3A4 inhibitors or other medications that could cause excessive heart‑rate reduction without proper monitoring.